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In vivo reprogramming of somatic cells into induced pluripotent stem cells (iPSC) holds vast
potential for basic research and regenerative medicine. However, it remains hampered by a
need for vectors to express reprogramming factors (Oct-3/4, Klf4, Sox2, c-Myc; OKSM) in
selected organs. Here, we report OKSM delivery vectors based on pseudotyped Adeno-
associated virus (AAV). Using the AAV-DJ capsid, we could robustly reprogram mouse
embryonic fibroblasts with low vector doses. Swapping to AAV8 permitted to efficiently
reprogram somatic cells in adult mice by intravenous vector delivery, evidenced by hepatic or
extra-hepatic teratomas and iPSC in the blood. Notably, we accomplished full in vivo
reprogramming without c-Myc. Most iPSC generated in vitro or in vivo showed tran-
scriptionally silent, intronic or intergenic vector integration, likely reflecting the increased host
genome accessibility during reprogramming. Our approach crucially advances in vivo
reprogramming technology, and concurrently facilitates investigations into the mechanisms
and consequences of AAV persistence.
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Reprogramming of cultured somatic cells into inducedpluripotent stem cells (iPSC) with a cocktail of transcrip-tion factors—originally Oct-3/4 (O), Klf4 (K), Sox2 (S) and
c-Myc (M)1—has become routine methodology, following a
seminal publication a decade ago2–4. Since then, numerous efforts
have been made to translate this key technology into living ani-
mals, fueled by two major expectations. First, one can anticipate
that tools for in vivo reprogramming will help to dissect the
intricate microenvironment that governs cellular (de-)differ-
entiation in healthy or diseased multicellular organisms. Second,
when stringently and spatio-temporally controlled, methods to
(de-)differentiate somatic cells in vivo and in situ will enable
novel, clinically relevant stratagems in regenerative medicine.
Illustrating this potential, several groups including our own5
have recently successfully established in vivo reprogramming
technologies and harnessed these to study cellular plasticity in
mice, yielding important implications for mammalian aging, tis-
sue regeneration and cancer development. These comprise our
discovery in OKSM-transgenic mice that cellular senescence or
lung injury create a tissue context which favors in vivo repro-
gramming in neighboring cells, possibly involving the senescence-
associated secretory phenotype (SASP) and secretion of interleukin-
6 (IL-6)6. A similar paracrine, cell-non-autonomous effect includ-
ing accumulation of senescent cells, enhanced cellular plasticity as
well as teratoma and dysplasia formation was noted by Chiche et
al.7 in OKSM-transgenic mice with acute or chronic muscle
damage.
Moreover, we6 and others7 consistently noted a higher inci-
dence of teratomas in older mice, implying that natural senes-
cence during aging likewise increases cellular plasticity in vivo.
Intriguingly, seminal work8 from the Belmonte group shows that,
vice versa, cyclic induction of in vivo OKSM expression in
transgenic mice can extend their lifespan and ameliorate hall-
marks of aging. This process of “molecular rejuvenation” or
“resetting of the aging clock” is characterized by improvements in
the nuclear envelope structure of OKSM-expressing cells, reduc-
tion of DNA damage, and higher resistance of mice to metabolic
disease and muscle injury8.
Other studies illustrate the power of in vivo reprogramming to
untangle the molecular and cellular mechanisms of cancer
initiation and progression to invasive phenotypes9,10. Ohnishi et
al.9 reported that premature termination of inducible OKSM
expression in transgenic mice resulted in kidney neoplasia
resembling Wilms tumor, suggesting the use of in vivo repro-
gramming to model cancer development. Marion et al.11
found that OKSM induction in transgenic mice triggered
telomere elongation as well as upregulation of telomere
protein TRF1 and telomerase RNA Terc. Interestingly, similar
telomere changes were concurrently observed in a mouse model
of pancreatic ductal adenocarcinoma. Finally, Tomokuni et al.12
injected Sendai viral OKSM expression vectors into mouse livers
and uncovered that Kras activation or p53 deficiency facilitate
in vivo reprogramming of liver cells, congruent with our own
data6.
Concomitantly, the power and promise of in vivo reprogram-
ming for regenerative medicine is showcased by encouraging
proofs-of-concept, ranging from OKSM-mediated interlineage
reprogramming—via plastic intermediate states—of cultured
human fibroblasts into various cell types (smooth muscle13,
endothelial14, mesodermal progenitor15, or neural progenitor16–18),
to exciting newest data that in vivo OKSM expression can trigger
cell and tissue regeneration in different organs in mice. In pio-
neering work, the Kostarelos group delivered OKSM-expressing
plasmids to liver or skeletal muscle of adult mice, using high-
pressure or intramuscular injection, respectively19–21. In the liver,
this led to transient upregulation of pluripotency markers
concurrent with a downregulation of hepatocyte markers, indicative
of successful in vivo reprogramming20. Indeed, extracted cells
showed pluripotent characteristics including teratoma formation in
immunocompromised mice19. Similarly, local injection of OKSM-
encoding plasmids into the gastrocnemius muscle led to induction
of proliferative, pluripotent-like cells in situ and accelerated tissue
regeneration in the surgically induced model of skeletal muscle
injury21. The effects were again transient, suggesting that the
reprogrammed cells had eventually differentiated and integrated
into the surrounding muscle tissue.
Others intracranially injected OSKM-encoding retroviruses
into mice with experimental brain injury22. This resulted in
in vivo reprogramming of microglia and other cells to stem cell-
like cells and their subsequent differentiation into functional
neurons in the neurocortex. Notably, unlike in the studies that
used plasmid DNA injection for OKSM expression19–21, mice
developed teratomas in the brain long after retroviral OKSM
delivery22, reminiscent of findings after persistent OKSM
expression in transgenic mice5,8,9. In contrast, Seo et al. observed
neither dysplasia nor tumors in OKSM-transgenic mice when
in vivo reprogramming was triggered in the lateral ventricle via
doxycycline infusion23. Instead, this led to generation of astro-
cytes and neuronal progenitors as well as behavioral functional
restoration after ischemic brain injury.
Collectively, these reports clearly illustrate the vast potential
of in vivo reprogramming technology for basic or applied
research and thus created considerable enthusiasm24–28. At the
same time, they highlight necessary improvements that will
enable a broader application, namely, (i) a need for new means
for in vivo OKSM delivery in a versatile, specific, potent and
clinically acceptable manner, and, once established, (ii)
improvements to the safety of the overall approach. As noted, to
date, the majority of in vivo reprogramming studies were
conducted in transgenic mice carrying drug-inducible, often
polycistronic expression cassettes that permit rapid and potent
induction of OKSM or of the individual factors5–9,23,29–32.
While useful for basic iPSC research, a common caveat is their
limited versatility due to the need for transgenic mouse strains.
Moreover, OKSM expression is driven from promoters lacking
cell specificity, causing simultaneous in vivo reprogramming in
multiple organs upon promoter induction and thus compli-
cating downstream phenotypic analyses. This was partially
overcome by groups who transiently expressed OKSM in mice
from plasmid DNA20,21, Sendai viral vectors12 or retroviral
vectors22. However, broader applicability in other organs or
species comprising humans is hampered by (i) a restriction of
local DNA injection to a few selected organs such as the liver or
the muscle, (ii) technically demanding and clinically undesir-
able delivery methods (hydrodynamic tail vein injection (DNA)
20, laparotomy and infusion into liver lobes (Sendai vectors)12,
or intracranial injection (retroviral vectors)22), and (iii) a lim-
itation to actively dividing cells (retroviral vectors)22. Conse-
quently, there remains a great demand for novel OKSM
expression and delivery systems that overcome the current
bottlenecks and, hence, facilitate a wider evaluation of in vivo
reprogramming in different mammalian species, up to clinical
translation in humans.
Here, we thus explored Adeno-associated viruses (AAV)33 as
vectors for in vivo OKSM delivery that complement and expand
the existing repertoire of tools, while offering a unique combi-
nation of assets including apathogenicity, independence of cell
division, amenability to genetic engineering and excellent safety
in humans, as documented in over 160 clinical trials34,35. Of note,
two prior studies used conventional AAV vectors with single-
stranded (ss) OKSM-encoding DNA genomes to reprogram
cultured cells and achieved efficiencies of up to 0.1%, but the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05059-x
2 NATURE COMMUNICATIONS |  (2018) 9:2651 | DOI: 10.1038/s41467-018-05059-x | www.nature.com/naturecommunications
in vivo capacity of these vectors was never investigated36,37. In the
present study, we demonstrate that when equipped with a com-
bination of robust capsid, promoter, genome structure (self-
complementary38–40 instead of single-stranded) and OKSM
cDNAs, AAV vectors can mediate highly efficient and wide-
spread in vivo reprogramming in adult mice, from a single
peripheral low-pressure administration. Our findings should
motivate numerous applications of AAV vector-mediated
in vivo reprogramming and should foster consecutive
attempts to maximize the safety of this technology, thus
ideally accelerating the clinical translation of this exciting
concept into humans.
Results
Design and validation of self-complementary AAV-OKSM
vectors. Traditional AAV vectors contain a ssDNA genome of up
to 5 kb in length which, in order to mediate transgene expression
in the target cell, has to undergo conversion to a double-stranded
(ds)DNA molecule. As this process is relatively slow and ineffi-
cient, we and others developed and now preferentially use an
alternative vector configuration, the so-called “self-com-
plementary” (sc)AAV vector genomes38–42. These carry a muta-
tion in one of the two viral DNA packaging and replication
signals, resulting in an encapsidated vector genome comprising
two inverted copies of the same transgene (see Supplementary
Fig. 1 for details). In the transduced cell, the latter rapidly anneal
to give rise to an expression-competent dsDNA, thus overcoming
the slow kinetics and limited efficiency of conventional ssAAV
vectors.
Fortunately, with sizes of the individual reprogramming factor
cDNAs between 1.0 and 1.4 kb, all four are compatible with the
restricted DNA packaging capacity of scAAV vectors of up to
2.4 kb. Accordingly, we engineered these to express mammalian
codon-optimized (hCO) OKSM cDNAs (one factor per vector)
from the cytomegalovirus (CMV) or the spleen focus-forming
virus (SFFV) promoter (Supplementary Fig. 1). We were not
concerned about having to use four individual AAV vectors
because of ample evidence that mammalian cells can be readily
co-transduced with multiple AAVs in vitro and in vivo43. As
additional proof, we documented highly efficient co-expression of
four distinct transgenes encoded by four different AAV vectors in
various cells, including primary mouse hepatocytes (Supplemen-
tary Fig. 2).
Vector functionality and efficiency were first evaluated
in vitro in mouse embryonic fibroblasts (MEF), a well-
established model system for cellular reprogramming. There-
fore, we harnessed a unique feature of the AAV system, i.e., the
ability to cross-package a given vector genome into any AAV
capsid—natural or synthetic—that mediates optimal gene
transfer into a specific target cell. Hence, for gene delivery into
MEF, we first screened a collection of synthetic AAV capsids
expressing a YFP (yellow fluorescent protein) reporter and
identified one as most efficient in these cells, AAV-DJ44 (a
chimera of AAV serotypes 2, 8, and 9; Supplementary Fig. 3a).
We then packaged the OKSM cDNAs into this capsid and
found that both promoters yielded similar numbers of
transgene-expressing MEF after transduction (Supplementary
Fig. 3b). However, intracellular expression levels were higher
with the SFFV promoter as compared to CMV, making it our
preferred choice.
We note that use of the AAV-DJ capsid resulted in strong
expression of reprogramming factors in over 80% of all cells, with
no evidence for cellular toxicity (Supplementary Fig. 3b). This
confirms our initial data with the YFP reporter (Supplementary
Fig. 3a) and illustrates the benefits of the AAV vector system,
considering that MEF are very hard to transfect with standard
reagents, whose efficiencies rarely exceed 20% and which are
frequently cytotoxic45.
Additionally, we tested various experimental conditions includ-
ing vector stoichiometry and doses (Supplementary Fig. 4 and
Supplementary Data 1, tab “In vitro”), with the best giving 0.2%
reprogramming efficiency and taking 13 days to yield cellular
colonies (Fig. 1a). To assess their pluripotency status, we evaluated
typical stem cell markers via immunofluorescence and/or reverse
transcription- (RT-)PCR (Fig. 1b, c; further examples are shown in
Supplementary Fig. 5). Of the 22 clones analyzed, 13 scored
positive for all pluripotency markers in both assays (Supplemen-
tary Table 1), while the other nine were probably partially
reprogrammed. Clones expressing the full set of markers exhibited
high in vitro differentiation capacity, as shown by embryoid body
formation and stainings of endodermal, mesodermal or ectoder-
mal structures (Fig. 1d). As additional evidence, we noted
spontaneous differentiation of iPSC (when cultured without LIF)
into beating cells, most likely cardiomyocytes (Supplementary
Movies 1, 2). Finally, we injected two iPSC clones (IVT-iPSC 1
and 12, Supplementary Data 1, tab “In vitro”) into the flanks of
nude mice (each clone was injected four times) and observed
formation of teratomas (cell masses originating from uncontrolled
proliferation and differentiation of pluripotent cells), proving the
pluripotency of the AAV-derived iPSC lines (Fig. 1e).
Highly potent in vivo reprogramming with scAAV-OKSM
vectors. We next produced the scAAV-SFFV-OKSM vectors
in large scale and high purity, to assess their ability to
reprogram cells in adult mice. Therefore, we again harnessed
the pseudotyping capability of the AAV system and now cross-
packaged all four vector genomes into the AAV serotype
8 (AAV8) capsid, due to its high efficiency and broad cell
specificity in vivo46. In a pilot experiment (Fig. 2a), we injected
18 C57BL/6 mice intravenously with two different doses
(nine mice each), i.e., 5 × 1010 or 2 × 1011 vector genomes (vg)
`per vector and mouse. We then sacrificed three mice per dose
2 or 4 weeks later for analyses of OKSM expression and
histopathological changes.
As expected, we observed a robust, dose-dependent expression
of all four reprogramming factors in the liver, the predominant
AAV8 target from peripheral delivery at the doses that we used
(Fig. 3a, b). With the exception of c-Myc, the average levels of
these factors declined from week two to four, indicative of
silencing of the ectopic expression cassettes as one would expect
during successful reprogramming. Moreover, we found numerous
patches in the livers of these animals that stained positive for Tfe3
and PCNA, markers for cellular pluripotency and proliferation,
respectively (Fig. 3c, d)47. Besides, we also detected ectopic Oct-3/
4 expression in various other tissues and cell types, such
as alveolar epithelial cells in the lung, fibroblasts in the
heart, or cells in the lamina propria in the gut (examples
for one dose and one time point are shown in Supplementary
Fig. 6). These observations are well in line with the known
biodistribution of AAV8 in mice46 and validate our rationale
for selecting this promiscuous serotype for our proof-of-
concept study.
Congruent with this, a comprehensive histopathological
analysis conducted by a trained pathologist revealed increased
proliferation and nuclear pleomorphism in multiple organs at
both time points (Supplementary Tables 2–4). Most notably, we
found teratomas in livers of mice treated with the high dose (2 ×
1011 vg) at 4 weeks post-injection (Supplementary Fig. 7a left).
Remaining mice were thus kept alive and monitored until
teratomas became palpable (summarized in Supplementary
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Table 5). Indeed, at week 7, 8 or 10 post-injection, all mice treated
with the higher vector dose had large teratomas in the liver
(Fig. 2a and Supplementary Fig. 7a). Histological analysis revealed
structures belonging to the three embryonic germ layers (Fig. 2b),
verifying that these were bona fide teratomas. Furthermore, we
could derive iPSC lines from teratomas, blood and bone marrow
from these animals (Supplementary Table 5, exemplified in
Fig. 2c). Injection of two teratoma-derived iPSC clones (IVV-
iPSC 9 and 14, Supplementary Data 1, tab “In vivo”) into the
flanks of nude mice (each clone was injected four times) resulted
in new teratomas, confirming that the AAV-derived in vivo iPSC
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Fig. 1 In vitro reprogramming of MEF using AAV-DJ SFFV-hCO-O/K/S/M vectors. a Experimental setup. MEF were transduced at days 1 and 3 after plating
with the four vectors, using a 4:1:1:1 O:K:S:M stoichiometry and one of the two indicated MOIs per experiment and per vector (with a four-fold excess of
Oct-3/4). At day 5, cells were transferred from a well of a 6-well plate to a 10 cm dish. Subsequently, medium was changed every other day to iPSC
medium with or without ascorbic acid (AA). First colonies with iPSC morphology were observed at day 13. The image shows a representative alkaline
phosphatase staining of clone IVT-iPSC 12 at passage 1. n= 4 for MOI 1 × 104 and n= 3 for MOI 1 × 103. b Confocal images exemplifying expression of Oct-
3/4, Sox2, Nanog and SSEA-1 in AAV-derived iPSC (again IVT-iPSC 12). Shown are merges of Hoechst and secondary antibody (Alexa Fluor 488-labeled)
stainings. Scale bars= 20 µm. c Reverse transcription-PCR analysis to detect expression of the depicted pluripotency markers. Shown are 10 representative
clones from the reprogramming series with ascorbic acid. See Supplementary Data 1 (tab “In vitro”) for details. Six of the ten shown clones (IVT-iPSC 19 to
22, 24, and 26) are positive for all markers. Hprt (Hypoxanthine-guanine phosphoribosyltransferase) served as housekeeper. C+ iPSC generated with a
lentiviral vector encoding human codon-optimized OKSM (positive control); C− untreated MEF (negative control); P, passage number. d Confocal images
showing expression of ectodermal, mesodermal, and endodermal markers in differentiated clone IVT-iPSC 1. Shown are merges of Hoechst and secondary
antibody (Alexa Fluor 488-labeled) stainings. Scale bars= 13 µm. Confocal images in b and d were taken with a Leica SP5 microscope with a ×40 oil
immersion objective and processed with ImageJ. e Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of
clone IVT-iPSC 1. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar= 100 µm. This figure contains elements
from Servier Medical Art (http://smart.servier.com)
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the highest incidence of teratomas (in line with our OKSM
expression and biodistribution data in Fig. 3), we also observed
extrahepatic teratomas in other tissues, including lung and
thymus (Supplementary Fig. 7a and Supplementary Table 5).
Finally, one mouse treated with the low dose (5 × 1010 vg) and
sacrificed 9 months post-injection had a teratoma in the
abdominal cavity arising from the pancreas or mesenteric lymph
nodes (Supplementary Fig. 7b). The fact that this mouse showed
no signs of reprogramming in the liver substantiates that scAAV8
vector-mediated in vivo reprogramming can also be achieved in
other tissues.
In vivo reprogramming with AAV depends on dose but not c-
Myc. We subsequently injected two new mouse cohorts with an
even higher dose of 1 × 1012 vg per vector and animal; moreover,
in one cohort, we replaced the c-Myc vector with one encoding
GFP (Fig. 2e, f). As a control, four mice were injected with our
previous high dose of 2 × 1011 vg per mouse. They all had to be
sacrificed due to palpable teratomas at weeks 7, 8, and 13 post-
injection, confirming our findings from the pilot study in Fig. 2a
(Supplementary Table 5 and Supplementary Fig. 7c). The three
mice injected with the 1 × 1012 vg OKSM dose had to be sacrificed
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formation in the liver (Fig. 2e) and in other organs (Supple-
mentary Table 5), illustrating that the efficiency and kinetics of
AAV-mediated in vivo reprogramming are dose-dependent.
Notably, one mouse treated with the high OKS vector dose
without c-Myc had a teratoma in the pancreas at month 12 post-
injection (Fig. 2f). Together with our successful isolation of iPSCs
from this teratoma (clone IVV-iPSC 15 in Supplementary Fig. 11
to 12 below), this shows that in vivo reprogramming is possible
even without the c-Myc oncogene.
Cellular origin of AAV-OKSM vector-induced teratomas. To
trace the cellular origin of the liver teratomas, we injected three
LSL-LacZ (loxP-stop-loxP) reporter mice with 2 × 1011 vg of the
scAAV8-OKSM cocktail per mouse, together with the same dose
of scAAV8 expressing Cre recombinase from the hepatocyte-
specific transthyretin (TTR) promoter48. At 7 to 8 weeks
post-injection, nearly 100% of hepatocytes were β-galactosidase-
positive (Fig. 2g, left histology panel), validating the lineage
tracing. Unlike the liver, teratomas displayed variable staining,
ranging from fully positive (Fig. 2g, right histology panel), to
mosaic or mostly negative (Supplementary Fig. 8). Furthermore,
some of the extra-hepatic masses of undifferentiated cells were
also β-galactosidase-positive, reflecting the hepatic origin of these
cells, which can migrate and colonize other tissues (Supplemen-
tary Fig. 9). We thus conclude that (i) hepatocytes can give rise to
teratomas and that (ii) some of the observed teratomas had a
polyclonal origin.
Analysis of AAV-OKSM vector integration events. Originally,
we had selected AAV vectors for in vivo OKSM delivery owing to
their remarkable biosafety, illustrated by the lack of serious adverse
events in over 160 clinical trials34,35. Corroborating this are studies
of AAV vector integration sites (IS) in mice, non-human primates
(NHP) and muscle or liver biopsies from vector-treated human
patients49–52, which revealed a genome-wide, random, safe and
low-frequency distribution of IS (up to 1 × 10−3 per cell on average
in human livers) without evidence of genotoxicity. Still, a
2015 study has sparked a controversial debate on whether inte-
gration of wild-type AAV2 DNA is correlated with human liver
cancers34,35,53,54. Besides, integration events were implied in the
two previous studies that used AAV/OKSM vectors to reprogram
mouse cells in vitro, but neither the consequences nor the IS were
characterized36,37.
Therefore, it was interesting to study whether our own AAV/
OKSM-derived cellular clones carried vector integrations as well.
Indeed, standard PCRs confirmed AAV vector persistence in all
33 clones analyzed (19 IVT-iPSC and 14 IVV-iPSC clones;
Fig. 4a, b). To ascertain whether the genomes were integrated
and, if so, to identify the precise genomic IS, we performed non-
restrictive linear amplification-mediated PCR (nrLAM-PCR)55
and target-enrichment sequencing (TES) on a subset of 22 clones.
This allowed us to define a total of 180 AAV IS in three quarters
of the in vitro-derived clones and in all of those generated in vivo
(Fig. 4c, Supplementary Data 2 and Supplementary Fig. 10).
Numbers of IS per clone varied from 2 to 40 (Fig. 4c and
Supplementary Data 2), consistent with data from AAV vector-
treated humans (Supplementary Note 1). Integrations were found
in clones that were partially or fully reprogrammed (Supplemen-
tary Data 1), implying they occur early during dedifferentiation.
Integrated vectors were scattered over all chromosomes without
hotspots (Fig. 4d and Supplementary Data 2), in line with the
random AAV vector integration profiles in mice, NHPs and
humans49–51, and arguing against clonal selection of AAV IS
in vitro or in vivo. Of the 180 IS, 85 (47.23%) were within genes
(Fig. 4e, sum of exons and introns), congruent with reported
values in mice between 41 and 72%50,56. Importantly, only 10 IS
(5.56%) were in exons, and of these, only two (1.11% of total
180 hits) or seven (3.89%) affected genes that are associated with
cancer (numbers depend on the cancer gene database that was
queried, see Supplementary Data 2 and Supplementary Note 1 for
more details). Notably, we observed no genuine tumors in any of
our mice, not even 9 months or later after OKS(M) vector
injection. The single exception is a mediastinal lymphoma in a 84
week-old mouse that was, however, most likely age- and not
vector-related (Supplementary Table 4). As a whole, our data are
thus congruent with the bulk of prior studies that found no
evidence for enhanced tumorigenesis in animals or humans after
AAV vector delivery and integration51. Besides, as expected for
properly reprogrammed iPSC, integrated ectopic OKSM vector
genomes were mostly transcriptionally silent, while endogenous
pluripotency markers were strongly induced (Supplementary
Fig. 11).
Discussion
Here, we aimed to remove a major roadblock that still hampers
the broader use of the exciting concept of in vivo reprogramming
and ultimately its clinical translation, namely, the lack of OKSM
delivery systems that (i) function in any mammalian species and
are independent of transgenic animals, (ii) can be targeted to any
desired cell or organ within an intact organism, (iii) are compa-
tible with tissue-specific and inducible promoters for additional
layers of control, and (iv) do not rely on complicated adminis-
tration schemes that are hard or impossible to apply in humans.
While all of the previously reported OKSM delivery tools meet a
subset of these demands, none of them affords the juxtaposition
of specificity and versatility that is required to take the field of
Fig. 2 In vivo reprogramming in mice using scAAV8 SFFV-hCO-O/K/S/M vectors. a Experimental setup. 38 weeks-old C57BL/6 male mice were injected
with 5 × 1010 (n= 9) or 2 × 1011 (n= 9) vg per vector and mouse. 2 and 4 weeks post-injection, three mice per dose and time point were sacrificed, and
their organs were extracted and analyzed histopathologically. Remaining mice were sacrificed upon appearance of palpable teratomas (week [w] 7, 8 and
10: 2 × 1011 vg group; month [m] 9: 5 × 1010 vg group). b Hematoxylin/eosin staining of liver teratoma section (mouse treated with 2 × 1011 vg and
sacrificed at week 8 post-injection). Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar= 100 µm. c iPSC
clone derived from a teratoma formed in the liver of the mouse from panel a. Scale bar= 100 µm. The shown clone is representative of 14 IVV-iPSC clones
that were derived from mice treated with the OKSM cocktail (four more [IVV-iPSC 15 to 18] were later obtained with OKS, Supplementary Data 1), six of
which were from teratomas (see also Fig. 3b). d Hematoxylin/eosin staining of a section of a subcutaneous teratoma generated in mice via injection of
clone IVV-iPSC 9. Structures belonging to the three embryonic germ layers are indicated by black arrows. Scale bar= 100 µm. e In vivo reprogramming
experiment using a high vector dose (1 × 1012 vg per vector and mouse) injected into 15 weeks-old C57BL/6 male mice (n= 3). Mice were sacrificed upon
appearance of palpable teratomas at week 6 post-injection. f Repeat of experiment from panel e, using a scAAV8 vector encoding GFP instead of c-Myc
(n= 3). All three mice were sacrificed at month 12 post-injection. One mouse (Supplementary Table 5, mouse #1, assay #6) had a teratoma (yellow
arrowhead) in the pancreas. g Histological sections of teratomas (extracted 8 weeks post-injection) from mice injected with a cocktail of scAAV8 vectors
encoding hCO-O/K/S/M or TTR promoter-driven Cre recombinase (n= 3). Sections were stained with hematoxylin/eosin and an anti-β-galactosidase
(left) or anti-Oct-3/4 antibody (right). Scale bars= 200 µm. This figure contains elements from Servier Medical Art (http://smart.servier.com)
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in vivo reprogramming to the next level. This combination of key
assets is provided, however, by recombinant AAV vectors, as
evidenced in the present work and supported by a wealth of
preclinical and clinical data from the past three decades, includ-
ing the recent commercialization of AAV-based gene therapy
products (Glybera, Luxturna).
Indeed, the data presented here demonstrate that when
appropriately pseudotyped, scAAV are very potent reagents for
in vitro and in vivo somatic cell reprogramming. In cultured cells,
the chimeric capsid AAV-DJ yielded robust reprogramming
efficiencies of 0.1 and 0.2% from low multiplicities of infection
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Fig. 3 Expression of the four reprogramming factors and evidence for reprogramming in mouse liver. a Detection of AAV-encoded hCO-Oct-3/4 (brown
staining) via immunohistochemistry in liver sections obtained from mice 2 or 4 weeks post-injection with 5 × 1010 (low dose) or 2 × 1011 (high dose) vg per
vector and mouse (n= 3 per dose and time point). Symbols are the same as in b. Nuclei were counterstained with hematoxylin. Scale bar= 100 µm.
b Quantification of the expression of AAV-encoded hCO-Oct-3/4, -Klf4, -Sox2 and -c-Myc by qRT-PCR. A delta Ct analysis was used in which the values
were normalized to the expression of a housekeeper gene (actin) and then expressed as fold-changes over the values (set to 1) for the low dose at 2 weeks
for each reprogramming factor. Each point represents a single mouse. Center values are means and error bars are S.D. Statistical analyses were performed
by one-way ANOVA with Tukey’s Multiple Comparison Test. *, p < 0.05; **, p < 0.01. c, d Evidence for reprogramming in livers of AAV-OKSM-treated mice
(2 × 1011 vg, sacrificed 8 weeks after administration) obtained via immunohistochemical detection of expression of Tfe3 (c), a marker for pluripotency, and
PCNA (d), a marker for proliferation. Note the largely overlapping patches of Tfe3- and PCNA-positive cells in the serial sections from the same liver of an
AAV-OKSM-treated mouse in the rightmost panels. Scale bars in the left and central panels= 100 µm, and in the right panels= 500 µm
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favorably to ssAAVs37, which gave 0.001 to 0.091% at MOIs of
2 × 104 to 2 × 105, respectively, and no iPSC colonies at 2 × 103.
Our lowest MOI was also three orders of magnitude lower (1 ×
103 vs. 1 × 106), and our reprogramming efficiencies higher (0.1%
vs. 0.036%), than those of an OKS-encoding ssAAV2 triple-
tyrosine mutant in mouse adipose stromal cells36, which are very
amenable to reprogramming57. The likely reason for the superior
performance of our vectors is the unique combination of
(i) potent capsid, (ii) strong promoter, (iii) scAAV genome, and
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Fig. 4 Analysis of AAV vector traces and integration sites in scAAV/OKSM-derived cellular clones. a PCR analysis of 19 clones generated in vitro and
analyzed at an early passage (between passage 0 and 6). Top gel: PCR with primers amplifying the whole cassette, from SFFV promoter to polyadenylation
signal. Three or four distinct bands are detected, which correspond to the four AAV reprogramming vectors used. Bottom gel: PCR to detect the Hprt
housekeeper (HK) gene. LVV, iPSC cells generated with a lentiviral vector encoding human codon-optimized OKSM; MEF, untreated MEF; H2O, control
PCR using water instead of DNA template. Sizes of a DNA marker are shown in kilobases (kb) on the left. The asterisks highlight IVT-iPSC clones which
may not have been fully reprogrammed (Supplementary Data 1). b PCR analysis of 14 AAV-iPSC clones generated in vivo using a MOI of 2 × 1011 and
analyzed at an early passage (between passage 2 and 4). See panel a for details as well as Supplementary Data 1 for information on all clones. c Graph
showing the number of AAV insertion sites (IS) identified by nrLAM-PCR or TES in the cellular clones shown in a (blue bars, generated in vitro) and
b (green bars, generated in vivo). d PhenoGram plot (generated with the tool http://visualization.ritchielab.psu.edu/phenograms/plot) depicting the
distribution of AAV IS across all mouse chromosomes, segregated into cellular clones generated in vitro (blue) or in vivo (green) (same color scheme as in
c). e Pie chart illustrating the proportions of AAV vector integrations (total n= 180) in exons, introns or intergenic regions. Of the 10 hits in exons, two
affected cancer-associated (CA) genes based on the Genecards (GC) database, or seven based on the Candidate Cancer Gene Database (CCGD) (see
Supplementary Data 2 for details)
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These factors also explain their high in vivo efficiency, evi-
denced by the appearance of bona fide teratomas in multiple
organs, even without c-Myc, circulating iPSC, and dose-
dependent increases in mitosis (indicative of early in situ repro-
gramming events). Teratomas are a most stringent endpoint of
in vivo reprogramming and are typically noted in OKSM-
transgenic mice5,6, exemplifying the ability of our vectors to
phenocopy this key readout from a simple and single peripheral
low-pressure administration.
Based on our proof-of-principle work, we envision
numerous applications of scAAV/OKS(M) vectors for cel-
lular reprogramming in animals and, ultimately, humans.
While teratomas—albeit poorly invasive and poorly meta-
static—and morbidity are obviously undesirable clinical
outcomes in patients and need to be avoided, data in OKSM-
transgenic mice show that these outcomes depend on the
extent and length of OKSM expression5,8. The next vector
generation should thus capitalize on the vast experience with
chemically and/or physically regulatable promoters in AAV
vectors.58–60, and exploit these to tightly control in vivo OKS
(M) expression. This should ideally allow to recapitulate the
concept of curtailed reprogramming via short-term, cyclic or
pulsed OKSM expression8,14–17, yielding partially dediffer-
entiated cells that no longer form tumors in vivo while
remaining capable of somatic differentiation. To this end, we
propose a second generation of scAAV vectors in which the
duration of OKSM expression is, e.g., stringently controlled
by light or which can be turned off at any given time by
means of CRISPR cleavage. While the present study already
shows that AAV-mediated ectopic OKSM expression is
inherently silenced over time (Fig. 3), as expected during
reprogramming, these or other newly introduced control
mechanisms should allow to accelerate this process and thus
further reduce the risk of in situ teratoma formation.
Other complementary safety measures should include mod-
ulation of vector dose, to additionally limit intracellular OKSM
expression and to concurrently minimize undesired transduction
of off-target organs. In this respect, we consider it highly bene-
ficial that our vectors express each factor individually, as it
facilitates fine-tuning of OKS(M) doses and ratios which may be
of value for partial reprogramming strategies17. Here, the dose
dependency of in vivo reprogramming efficiency, specificity and
safety with scAAV8-OKSM vectors was clearly illustrated by the
different outcomes observed at our doses of 5 × 1010, 2 × 1011 or
1 × 1012 vg per vector and mouse, i.e., 20-fold dose range. Our
findings on dose-dependent AAV8 promiscuity in mice are well
in line with previous data, e.g., from the Kay group who noted a
strong liver tropism in animals injected with 3 × 1011 vg (com-
parable to our dose of 2 × 1011 and the ensuing results), but a very
broad transduction in other tissues at 7 × 1012 vg46 (see also
Supplementary Fig. 7c).
Consequently, a rewarding additional and complementary
measure to enhance specificity and safety of future AAV-OKSM
iterations will be to select from the wealth of AAV capsids and
promoters with desired biodistribution (here, the broadly active
AAV8 and SFFV were merely used for proof-of-concept), and to
also combine this with miRNA-based detargeting strategies61.
Importantly, unlike all other viral or non-viral vector systems that
have been used for in vivo OKSM delivery before, this will offer
the option to target OKSM expression to virtually any organ of
choice, following a simple and single intravenous administration.
This is owing to the high amenability of the AAV capsid and
genome to genetic diversification62, permitting to apply a wide
portfolio of molecular evolution technologies and to select
superior capsids in any desired tissue, as already demonstrated
extensively in liver44, brain63, eye64, heart65, ear66 or skeletal
muscle67, among many others. Most recently, by high-throughput
in vivo screening of comprehensive AAV capsid libraries, we have
also identified synthetic AAV capsids that outperform the best
wild-types in skeletal muscle, heart and diaphragm, or that
mediate highly selective transgene expression in specific cell types
within the murine liver (unpublished data).
We are thus highly optimistic that these and other mod-
ifications will ultimately provide sufficient control over
in vivo OKSM delivery and expression, and thereby not only
enable a broader use of in vivo reprogramming technology in
any desired animal model, but also facilitate and accelerate
its application for therapeutic reprogramming. Already, a
rapidly increasing number of reports showcase the tre-
mendous potential of direct in vivo reprogramming in mul-
tiple tissues such as liver, muscle or brain, including repair
and functional recovery after tissue damage, amelioration of
age-related phenotypes as well as increased resistance to
metabolic disease in mice7,8,19–23. Nonetheless, these pre-
vious studies and associated commentaries24–27 also con-
sistently pointed out the need for better, clinically acceptable
OKSM delivery means, a critical gap that may be closed in
the future based on the AAV-OKSM vectors reported here.
Importantly, this may then also help to alleviate concerns with
alternative strategies such as transplantation of ex vivo differentiated
iPSC or embryonic stem cells, which often fail to mature completely,
trigger immune rejection (in the case of allogenic or xenogenic cells)
and/or do not engraft and survive long-term22,23,27,68. Partial or
transient in vivo reprogramming may also be beneficial over lineage
conversion approaches as these do not allow for expansion of the
transdifferentiated cells, and efficiencies are typically low2. In con-
trast, controlled, vector-mediated in vivo dedifferentiation of cells
towards plastic intermediates will yield mitotically active progenitor
populations with high multi-lineage differentiation capacity and thus
numerous medical implications. Last but not least, in vivo generated
stem cells could represent a new source of autologous cells that
alleviates constraints of cell culture-derived iPSC, such as ex vivo
GMP requirements, pathogen contamination or concerns about iPSC
antigenicity69.
Still, before these concepts can progress to clinical application
in humans, safety and other lasting repercussions of introducing
potent reprogramming factors in vivo will have to be monitored
prudently, also in larger animal models. Next to the aforemen-
tioned risk of uncontrolled proliferation and teratoma formation,
one parameter that requires particular attention is the propensity
of cells to stably integrate AAV vector DNA during dediffer-
entiation, as noted before and here in vitro36,37, and as further
observed by us in the present work in vivo. Most importantly, the
frequencies and sites of AAV vector integration detected in the
current study are highly similar to those reported50 in biopsies
from humans who had received Glybera, a therapeutic AAV1
vector that was granted marketing authorization by the European
Commission in 2012. Combined with our notions of very rare
integration into exons of cancer-associated genes and the com-
plete absence of signs of tumorigenesis in our mice, we thus
carefully conclude that the use of AAV/OKS(M) vectors for direct
in vivo reprogramming may be safe from a genotoxicity stand-
point, or at least no more hazardous than any conventional AAV
gene transfer/therapy (see also Supplementary Note 1).
Methods
Cell culture. All cell lines and primary cells were incubated in a humidified
atmosphere at 37 °C and 5% CO2. In general, cells were passaged two or three times
a week by washing them once with sterile 1 × PBS (Life Technologies GmbH,
Paisley, UK), incubating with 0.25% trypsin/EDTA (Life Technologies GmbH) for
5 (HEK293T cells70, CRL-3216, ATCC, Manassas, VA, USA) to 10 min (mouse
embryonic fibroblasts, MEF), re-suspending the trypsinized cells in fresh medium
(DMEM (Life Technologies GmbH), 10% FBS (Biochrom, Cambourne, UK) and
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1% penicillin-streptomycin (Life Technologies GmbH)) and re-seeding them at the
desired density.
Mouse embryonic stem cells (mESC E14TG2α71, CRL-1821, ATCC) were
cultured in gelatin-coated dishes with KnockoutTM DMEM supplemented with
15% KnockoutTM Serum Replacement, 1% penicillin-streptomycin, 1% L-
glutamine, 1% Non-essential Amino Acid Solution, 50 µM β-mercaptoethanol (all
Life Technologies GmbH) and 5 × 105 units LIF (Merck Millipore, Darmstadt,
Germany). They were passaged as described above two or three times a week on
demand.
For the reprogramming experiments, primary MEF from C57BL/6 mice (kind
gift from Annabel Grewenig, German Cancer Research Center, Heidelberg,
Germany) at passage 3 were seeded in 6-well plates (Greiner Bio-One,
Frickenhausen, Germany) coated with gelatin (Sigma-Aldrich, Munich, Germany)
at a density of 1 × 105 cells per well (day 0). The next day (day 1), the cells were
transduced with the reprogramming AAV vectors or, as control, 5 µl of a crude
lysate of the lentiviral vector pRRL.PPT.SF.hOKSMco-idTom-pre-FRT (kind gift
from Axel Schambach, Hannover Medical School, Germany). The multiplicity of
infection (MOI) for each AAV vector was 1 × 103 or 1 × 104 viral genomes (vg) per
cell, except for AAV-DJ SFFV-hCO-Oct-3/4 for which 4 × 103 or 4 × 104 vg per cell
were used (corresponding to a O:K:S:M stoichiometry of 4:1:1:1). Cells were then
centrifuged at 1231 × g for 15 min. 2 days later (day 3), the medium was changed to
mESC medium (see above), and the cells were transduced again as described above.
After 2 days (day 5), the cells from each well of the 6-well plate were transferred to
gelatin-coated 10 cm dishes. After this point, the medium (in some cases
supplemented with ascorbic acid to a final concentration of 50 mg/ml) was changed
every other day until iPSC colonies were observed. Single colonies were picked and
transferred to gelatin-coated 12-well plates with feeder layers.
To prepare the latter, MEF were grown to 80% confluency in T75 cell culture
flasks (Greiner Bio-One). One ml of medium was then removed and 1 ml
mitomycin C (Sigma-Aldrich) was added to a final concentration of 10 µg/ml. The
cells were incubated for 2 h at 37 °C and 5% CO2. Then, they were washed twice
with sterile 1 × PBS, trypsinized, counted and seeded in gelatin-coated 6-well plates
at a density of 2.5 × 105 cells per well. To passage iPSC, the medium (iPSC medium
plus 2i, i.e., 1 µM PD0325901 and 3 µM CHIR99021 (Axon Medchem, Groningen,
Netherlands)) was removed, the cells were washed with 2 ml sterile 1 × PBS and
incubated with 500 µl 0.25% trypsin/EDTA for approximately 10 min at 37 °C and
5% CO2. The trypsinized cells were then collected with 1 ml sterile 1 × PBS and
trypsin was inactivated by adding 1 ml medium. The cells were centrifuged for
5 min at 335 × g, resuspended in 8 ml fresh medium and re-added to the 6-well
plates. To separate the feeder layers from the iPSC, the cell suspension was
incubated for 2 h at 37 °C and 5% CO2. Then, the supernatant containing the iPSC
was harvested and re-seeded at the desired density on gelatin-coated dishes with
fresh feeder layers.
To differentiate iPSC into the three embryonic germ layers, embryoid bodies
(EB) were prepared using hanging drops. To this end, iPSC were passaged as
described above and diluted in EB medium (KnockoutTM DMEM, 15%
KnockoutTM Serum Replacement, 1% L-glutamine, 1% Non-essential Amino Acid
Solution) to a density of 600 cells per 20 µl (or 3 × 104 cells per ml). Using a
multichannel pipette, 70 to 100 drops of 20 µl each were deposited onto the lid of a
bacterial petri dish (Greiner Bio-One). Then, 20 ml of sterile 1 × PBS were poured
into the petri dish to maintain humidity, and the dish was closed by carefully
placing the drop-containing lid on top. The hanging drops were incubated for
3 days at 37 °C and 5% CO2. Afterwards, they were harvested with 4 ml EB medium
per lid (three lids containing hanging drops were combined into a single petri dish)
and cultured in suspension for three additional days in 10 cm dishes. Next, the EB
were transferred to adherent culture. For this purpose, they were harvested into
their own medium, transferred to a conical tube, let sediment for around 10 min at
room temperature, resuspended in fresh EB medium and transferred to gelatin-
coated black µ-Plate 96-well plate (Ibidi, Martinsried, Germany), aiming to obtain
one to two EB per well. The EB were incubated at 37 °C and 5% CO2 for 1 to
2 weeks. During this period, medium was changed every other day, and EB were
monitored regularly for signs of differentiation. Once differentiated structures were
observed, the EB were stained with antibodies against markers of endoderm,
mesoderm or ectoderm, following the immunostaining protocol described below.
AAV vector production and titration. AAV vectors for capsid screening were
produced in small scale by triple-transfecting HEK293T cells using poly-
ethylenimine (PEI) with (i) an AAV vector plasmid, (ii) an AAV helper plasmid
expressing rep and cap, and (iii) an adenoviral helper plasmid72. The capsids used
were AAV-DJ44, AAV-DJ with a tyrosine-to-phenylalanine mutation of tyrosine
500 (equivalent position in the AAV-2 capsid gene, Y500F73,74), AAV2 with
tyrosine-to-phenylalanine mutations of tyrosines 444 and 500 (Y444+ 500F) or of
tyrosines 500 and 730 (Y500+ 730 F)73,74, and AAV1 with insertions of peptides
NDVRSAN (P4) or NDVRAVS (P5) into an exposed capsid region (between
AAV1 residues D590 and P591).
For in vitro experiments, AAV vectors were produced in medium scale and
purified through iodixanol gradient density centrifugation, and full AAV particles
were collected from the 40% iodixanol phase75.
For in vivo experiments, AAV vectors were produced in large scale, by triple-
transfecting 30 15 cm dishes using PEI72,75 and purifying resulting vector particles
using cesium chloride (CsCl) gradient density centrifugation44. Samples with a
refractive index between 1.3711 and 1.3766 comprising DNA-containing AAV
particles were pooled and dialyzed against 1 × PBS, using Slide-A-Lyzer Dialysis
cassettes (Thermo Fisher Scientific, St. Leon-Rot, Germany) according to the
manufacturer’s instructions. The dialysis procedure comprised a 30 min incubation
at room temperature with no stirring, followed by several periods with gentle
stirring at 4 °C and replacement of 1 × PBS in between: 1, 2 h, overnight, 2, 2 h.
Upon completion of the dialysis, the sample was removed from the cassette and
concentrated using an Amicon® Ultra Centrifugal Filter (Millipore, Billerica, MA,
USA), which was previously equilibrated by washing it twice with 15 ml 1 × PBS.
Several centrifugation steps at 400 × g for less than 2 min were used to reduce the
volume of the sample to 1 to 1.5 ml. The purified AAV vectors were finally
aliquoted and stored at −80 °C.
The AAV vectors purified with either iodixanol or CsCl gradients were titered
using quantitative real-time PCR (qPCR). For this purpose, the DNA was extracted
from the AAV vectors using an alkaline lysis protocol, in which 10 µl of the AAV
vector sample were mixed with 10 µl TE buffer and 20 µl 2 M NaOH, followed by
incubation for 30 min at 56 °C. The alkaline lysis was stopped by adding 38 µl 1M
HCl, and the final volume was adjusted to 1 ml by adding 922 µl RNase-free H2O.
Iodixanol-purified samples were further diluted 1:10 with H2O to avoid
interference of the iodixanol with the qPCR reaction. As a negative control, RNase-
free H2O was used, and as a positive control an AAV vector whose titer was already
known. The qPCR was performed using the SensiMixTM II Probe Kit (Bioline,
London, UK). Primer pairs were CMV_5′ and CMV_3′, SFFV_5′ and SFFV_3′, or
TTR_5′ and TTR_3′ (see Supplementary Table 6 for all primer sequences), and
probes were CMV (FAM-agtcatcgctattaccatgg-BHQ1), SFFV (FAM-acctgaaatgaccc
tgcgccttatttgaattaac-BHQ1) or TTR (FAM-tttggagtcagcttggcagggatca-BHQ1)
(FAM, Fluorescein amidite; BHQ1, black hole quencher 1). The reaction mixes
were prepared in triplicates and contained (per reaction): 1 × SensiMix II Probe Kit,
0.4 µM of each primer, 0.1 µM of the probe, 1.43 µl of the alkaline lysis reaction (see
above) and RNase-free H2O to adjust the final volume to 10 µl. The standard curve
was prepared by making serial dilutions of an appropriate plasmid, with numbers
of molecules per reaction ranging from 5 × 103 to 5 × 108. The qPCR was
performed in a Rotor-Gene Q (QIAGEN, Hilden, Germany) using the following
amplification conditions: 10 min at 95 °C, followed by 40 cycles of denaturation at
95 °C for 10 s and annealing/extension at 60 °C for 20 s. The results were analyzed
using the Rotor-Gene Q Series Software 1.7 (QIAGEN). A standard curve was
considered reliable when its R2 was greater than 0.985. To calculate titers of viral
genomes per ml (vg/ml), the obtained concentration was multiplied by 7 (a 10 µl
reaction contained 1.43 µl of the original alkaline lysis reaction), 100 (dilution after
alkaline lysis), 100 (to convert 10 µl into 1 ml) and 10 (only for samples purified
with iodixanol gradients diluted 1:10 after alkaline lysis).
Cloning procedures. The human codon-optimized OKSM cDNAs were PCR-
amplified from plasmid pRRL.PPT.SF.hOKSMco-idTom-pre-FRT76 and cloned
into a self-complementary (sc)AAV backbone using BamHI/SalI restriction sites.
The SFFV promoter-containing reprogramming plasmids were cloned in two steps.
Firstly, the SFFV promoter together with the human codon-optimized Oct-3/4
cDNA were PCR-amplified from lentiviral plasmid pRRL.PPT.SF.hOKSMco-
idTom-pre-FRT with primers SFFV_For_EcoRI and hOct4_Rev_SalI, and cloned
into the EcoRI/SalI-digested scAAV backbone. Secondly, the other three repro-
gramming factors were PCR-amplified with primers hKlf4_For_BamHI and
hKlf4_Rev_SalI, hSox2_For_BamHI and hSox2_Rev_SalI, or hcmyc_For_BamHI
and hcmyc_Rev_SalI, respectively, and cloned into the scAAV-SFFV-hCO-Oct-3/4
plasmid via BamHI/SalI (a BamHI site was present in the original pRRL.PPT.SF.
hOKSMco-idTom-pre-FRT plasmid between the SFFV promoter and the Oct-3/4
cDNA) (see Supplementary Table 6 for primer sequences). The scAAV-SFFV-GFP
vector was cloned by isolating the GFP cDNA from pBS-H1-TuD-empty-GFP77 via
BamHI/SalI digestion and ligating it into BamHI/SalI-digested scAAV-SFFV-hCO-
Oct-3/4.
Reverse transcription-PCR (RT-PCR). RT-PCR was performed to detect
expression of pluripotency markers in iPSC. For this purpose, cell pellets harvested
from a 6-well plate were resuspended in 1 ml QIAzol Lysis Reagent (QIAGEN).
RNA was extracted using the miRNeasy Mini Kit (QIAGEN) following a supple-
mentary protocol for purification of total and small RNA from serum or plasma
(https://www.qiagen.com/us/resources/resourcedetail?id=baa5450e-739b-4a11-
8006-745796a56554&lang=en; this protocol was used due to the low amount of
starting material since iPSC were harvested after differential sedimentation). After
resuspension in 1 ml QIAzol Lysis Reagent, the samples were incubated for 5 min
at room temperature. Then, 200 µl chloroform were added to the homogenate, and
the tube was closed securely and shaken vigorously for 15 s. This was followed by a
2 to 3 min incubation at room temperature and a 15 min centrifugation at 13,400 ×
g and 4 °C. Subsequently, 770 µl of the transparent upper phase containing the
RNA were transferred to a new tube, and 1155 µl 100% ethanol were added and
mixed thoroughly by pipetting up and down. The sample was then transferred to
an RNeasy Mini spin column and centrifuged for 15 s at 9300 × g and room
temperature. An on-column DNase I digestion was performed following the
instructions in Appendix D of the miRNeasy Mini Handbook (QIAGEN). Finally,
the column was washed twice with 500 µl buffer RPE, residual RPE buffer was
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eliminated by an additional centrifugation step, and the RNA was eluted in 30 µl
RNase-free H2O.
Reverse transcription was performed using the Tetro cDNA Synthesis Kit
(Bioline). The cDNA synthesis reaction had a total volume of 20 µl and contained
240 ng RNA, 1 µl Random Hexamer Primer Mix, 1 µl 10 mM dNTP mix, 1 µl
Ribosafe RNase Inhibitor, 1 µl Tetro Reverse Transcriptase (200 U/µl) and 4 µl 5 ×
RT Buffer. The reaction was incubated for 10 min at 25 °C, followed by 30 min at
45 °C and 5min at 85 °C for termination. The subsequent PCR was performed
using published primers4. The PCR reaction contained 1 to 3 µl cDNA, 4 µl 5 ×
Phusion HF buffer (Thermo Fisher Scientific), 1 µl forward primer (10 nM), 1 µl
reverse primer (10 nM), 0.4 µl 10 nM dNTPs (NEB, Frankfurt, Germany), 0.6 µl
DMSO (Thermo Fisher Scientific), 0.2 µl Phusion Hot Start II DNA polymerase
(Thermo Fisher Scientific) and H2O to a total volume of 20 µl. PCR conditions
were initial denaturation at 98 °C for 30 s, followed by 30–35 cycles of denaturation
at 98 °C for 10 s, primer annealing at 55 °C for 15 s and extension at 72 °C for 30 s.
This was followed by a final extension step at 72 °C for 8 min. PCR products were
separated in a 2% agarose gel with ethidium bromide and visualized with the Gel
Doc XR (Bio-Rad, Munich, Germany).
Quantitative reverse transcription PCR (qRT-PCR). qRT-PCR was used to
detect expression of the exogenous reprogramming factors and pluripotency
markers in iPSC. Reverse transcription was performed using the Tetro cDNA
Synthesis Kit (Bioline) as described above, but using 500 ng RNA extracted with the
AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN) following the manufacturer’s
instructions. Each qRT-PCR reaction contained 6.25 µl Power SYBR Green PCR
Master Mix (Thermo Fisher Scientific), 1.75 µl of a primer mix containing the
forward and reverse primers (Supplementary Table 6) at a concentration of 10 µM,
1.25 µl cDNA and 3.25 µl H2O. The qRT-PCR reaction was run in an Applied
Biosystems StepOnePlus Real-Time PCR system (Thermo Fisher Scientific).
To detect the expression of the exogenous reprogramming factors in vivo,
organs were homogenized with the Precellys Evolution Homogenizer (Bertin
Instruments, Frankfurt, Germany), using 2.8 mm zirconium oxide beads and 1 ml
of TRIzol Reagent (Ambion, Life Technologies GmbH). RNA was extracted
following the manufacturer’s instructions. RNA was treated with TURBO DNA-
free Kit (Ambion, Life Technologies GmbH) to remove genomic DNA
contamination. For cDNA synthesis, 1 µg of each RNA was used and reverse
transcription was performed using 4 µl of iScript RT Supermix (Bio-Rad) in a 20 µl
reaction. The reaction was incubated at 25 °C for 5 min for priming, then at 46 °C
for 20 min for reverse transcription and finally at 95 °C for 1 min to inactivate the
reverse transcriptase. The cDNAs were diluted 1:10 in RNase-free H2O. Each qRT-
PCR reaction contained 5 µl of Applied Biosystems PowerUp SYBR Green Master
Mix (Thermo Fisher Scientific), 2 µl of cDNA at a concentration of 5 ng/µl and
0.5 µl of each primer (forward and reverse) at a concentration of 10 µM. The qRT-
PCR reaction was run in an Applied Biosystems 7900HT Real-Time PCR system
(Thermo Fisher Scientific).
Non-restrictive linear amplification-mediated PCR (nrLAM-PCR). The nrLAM-
PCR reaction24 consisted of a linear PCR (primers P2 and P3, Supplementary
Table 6), followed by magnetic capture of the DNA. Then, the PCR products were
ligated to a bar-coded linker cassette using circLigase (Epicentre, Madison, WI,
USA). This was followed by two exponential PCRs (primers P5 and LCI were used
in the first exponential PCR, and primers P4 and LCII in the second; Supple-
mentary Table 6) and by a final Mega PCR in which bar-coded primers were used
(MiSAAV primers and MegaLinker primer; Supplementary Table 6). To rule out a
contamination of the controls, a small fraction of the Mega PCR products were run
on a 2% agarose gel. The rest was purified using the Agencourt AMPure XP PCR
purification system (Beckman Coulter, Brea, CA, USA) following the manu-
facturer’s instructions. In total 50 ng of each sample were pooled and sequenced on
a MiSeq Illumina platform at the Deep Sequencing Core Facility of the German
Cancer Research Center (Heidelberg, Germany).
Target Enrichment Sequencing (TES). Genomic DNA was extracted using the
AllPrep DNA/RNA/miRNA Universal Kit (QIAGEN), and the concentration was
measured in a Qubit (Life Technologies GmbH). To perform TES, 1 µg genomic
DNA was fragmented with a S220 Focused-ultrasonicator (Covaris, Woburn, MA,
USA) to an average peak size of about 250 bp. Libraries were prepared with the
SureSelectXT2 Reagent Kits (Agilent Technologies, Waldbronn, Germany). Vector-
containing fragments were enriched using custom SureSelect baits (Agilent
Technologies) complementary to the AAV vector used for reprogramming (in
combination with other vector baits). The libraries were submitted to the
sequencing facility of the German Cancer Research Center for 100 bp paired-end
sequencing on a HiSeq 2000. Insertion sites were determined with our in-house
“GENE-IS” pipeline78.
Immunostaining and microscopy. Alkaline phosphatase stainings were performed
using the Alkaline Phosphatase Staining Kit II (Stemgent, Cambridge, MA, USA)
in 24-well plates (Greiner Bio-One) following the manufacturer’s instructions.
Images were taken with an AmScope microscope digital camera MD800E
(AmScope, Irvine, CA, USA) attached to an Olympus CKX41 microscope
(Olympus, Hamburg, Germany).
Immunostainings to detect pluripotency or differentiation markers were
performed on iPSC cultured in black µ-Plate 96-well plates (Ibidi) coated with
gelatin. Cells were washed twice with ice-cold 1 × PBS and fixed with 100%
methanol for 7 min at −20 °C. Methanol was rinsed with acetone for 20 s at
−20 °C. Once fixed, the cells were washed three times with PBST (1 × PBS, 0.1%
Tween20) for 5 min at room temperature. Then, they were blocked for 30 min at
room temperature with blocking buffer (1 × PBS, 0.5% BSA, 1% FCS and 0.1%
Triton X-100) and incubated overnight at 4 °C with the primary antibody.
Antibodies to detect pluripotency markers were anti-Oct-3/4 (1:150, sc-8628, Santa
Cruz Biotechnology, Heidelberg, Germany), anti-Nanog (1:150, ab80892, Abcam,
Cambridge, UK), anti-Klf4 (1:20, AF3640, R&D Systems, Wiesbaden-Nordenstadt,
Germany), anti-Sox2 (1:200, AB5603, Merck), and anti-SSEA-1 (1:150, sc21702,
Santa Cruz Biotechnology). Antibodies to detect differentiation markers were anti-
βIII-tubulin (1:50, sc-51670, Santa Cruz Biotechnology), anti-α-smooth muscle
actin (1:400, A 5228, Sigma-Aldrich), anti-FoxA2 (1:50, AF2400, R&D Systems).
All antibodies were diluted in blocking buffer. Following incubation with the
primary antibody, cells were washed twice with blocking buffer and incubated for
4 h at 4 °C with the secondary antibody (1:500, anti-rabbit, anti-goat or anti-mouse
Alexa Fluor 488-conjugated, Life Technologies GmbH). Then, the cells were
washed twice with ice-cold PBST, incubated for 3 min with 1 × PBS containing
Hoechst 33258 (Life Technologies GmbH) diluted 1:3000 and washed again with
ice-cold 1 × PBS. The cells were imaged and stored (at 4 °C) immersed in 1 × PBS.
Images were taken with an Olympus Biosystems IX81 microscope with a 10 ×
objective or with a Leica SP5 confocal microscope (Leica, Mannheim, Germany)
with a 40 × oil immersion objective.
Flow cytometry. To analyze AAV vector-transduced cells by flow cytometry they
were cultured and transduced in 96-well plates. To prepare them for the analysis,
the media was removed, they were washed once with 1 × PBS, trypsinized with
40 µl 0.25% trypsin/EDTA for 5 to 10 min and re-suspended in 160 µl 1% BSA in
1 × PBS. Data were acquired with the Cytomics FC500MPL analyzer and the MXP
software (both Beckman Coulter). First, size and granularity of the cells were
determined by plotting the forward and side laser light scatter. Cells with the
largest size and highest granularity were gated as “living cells”. Then, fluorescence
of the living cells was analyzed by plotting the green vs. the red channel. The gate
for positive cells was established by measuring an untransduced control and
excluding the area from the gate in which events appeared. The untransduced
control was also used to determine the appropriate voltage. The acquisition
parameters were set to measure 2 × 104 events or to acquire for 60 s and to mix the
sample three times before acquiring. The volume used for the analysis was 100 µl.
Cloning of fluorophore-encoding vectors. Self-complementary AAV vectors
expressing a CMV promoter-driven gfp (dsAAV-GFP) or yfp cDNA (dsAAV-YFP)
were kindly provided by Kathleen Börner (Heidelberg University Hospital, Hei-
delberg, Germany). Variants of these expressing either mScarlet or mTurquoise
were subsequently generated as follows. The mScarlet cDNA was PCR-amplified
from vector pmScarlet_C1 (kind gift from Dorus Gadella [University of Amster-
dam, Netherlands]; Addgene plasmid # 85042) using primers mScarlet_fw and
mScarlet_re. mTurquoise was PCR-amplified from vector pmTurquoise2-C1 (kind
gift from Dorus Gadella; Addgene plasmid # 60560) using primers mTurquoise_fw
and mTurquoise_re (see Supplementary Table 6 for primer sequences). Sequences
in capital letters denote overhangs containing restriction sites for cloning, where
needed. Amplicons were digested with AgeI/NheI and ligated into AgeI/NheI-
linearized dsAAV-GFP, yielding vectors dsAAV-mScarlet and dsAAV-
mTurquoise.
HEK293T cells (25,000 cells per compartment) and primary hepatocytes
(10,000 cells per compartment) were seeded into 8-well chamber slides (Ibidi,
#80826). The next day, cells were transduced with Iodixanol-purified AAV-DJ
vectors encoding a CMV promoter-driven mTurquoise, egfp, eyfp or mScarlet
cDNA (one per vector, see above) either separately (MOI 1 × 104) or with all four
viruses in combination (MOI 1 × 104 each). 48 h post-infection, fluorescence was
observed using a Leica SP8 confocal laser scanning microscope equipped with a
UV, argon and solid state laser and a HC PL APO 40 × oil objective (N/A= 1.3).
Laser power used to excite the different fluorophores in the HEK293T and
primary hepatocytes samples, respectively, was 3.5%/36.5% for the 405 nm UV
laser (mTurquoise excitation); 3.7%/7.6% for the 488 nm argon laser line (EGFP
excitation); 0.1%/0.1% for the 514 nm argon laser line (EYFP excitation) and 0.3%/
0.9% for the solid state green laser (mScarlet excitation). Detection wavelengths
were set as follows: 441 to 479 nm for mTurquoise, 491 to 505 nm for EGFP, 550 to
569 nm for EYFP, and 583–715 nm for mScarlet. Gain was set to 900 for each
detector. These settings were chosen to minimize bleed-through between the four
channels under the used experimental conditions. To visualize cells expressing all
four fluorophores (“overlap” in Supplementary Fig. 2), a threshold was applied to
each channel using ImageJ (version 1.51n; http://imagej.nih.gov/ij). Pixels that were
above threshold in all four channels were then projected in white color onto the
corresponding bright-field image.
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Animal experiments. Animal experimentation was performed at the CNIO
(Madrid, Spain) according to the protocol (PROEX125/14) approved by the CNIO-
ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA). Wild-type
male mice of 15 weeks (or 38 weeks in the pilot experiment) of age were retro-
orbitally injected with the indicated AAV8 vector doses. For the tracing
experiments, we used a GtRosa26tm1Sor (R26R) reporter transgenic mouse model79.
All mice used were in a pure C57BL/6 J.Ola.Hsd genetic background. Mice were
monitored and sacrificed at the indicated time points or when teratomas were
palpable. For subcutaneous teratomas, iPSCs were trypsinized and 1 × 106 cells,
suspended in iPSC medium, were subcutaneously injected into the flanks of
immunocompromised nude mice (Hsd: athymic Nude/Nude from Harlan Ibérica
(now Envigo, Valencia, Spain)). iPSC cells had been previously cultured in 2i
medium (see above) for at least 10 days. Teratomas were isolated when the dia-
meter reached at least 1.5 cm and processed for histological analysis.
Isolation of iPSC from mouse blood and bone marrow. Peripheral blood
(0.3–0.5 ml) was collected directly from the heart of mice at the time of necropsy,
and bone and marrow cells were obtained from the femora and tibiae by flushing
with medium. Blood samples were subjected to two rounds of erythrocyte lysis in
ammonium chloride solution (STEMCELL Technologies, Vancouver, BC, Canada).
A first lysis round with 10 ml for 15 min and at room temperature was followed by
centrifugation (5 min at 219 × g) and a second lysis round with 3 ml for 15 min and
at room temperature. Samples were then neutralized by adding 12 ml iPSC med-
ium. Bone marrow samples were subjected to one round of erythrocyte lysis in
ammonium chloride solution (3 ml for 5 min), followed by neutralization with
12 ml iPSC medium. Cells were pelleted, resuspended and plated on gelatin-coated
plates with feeder layers. They were cultured in iPSC medium until iPSC colonies
appeared. Cultures were routinely tested for mycoplasma and were always negative.
Immunohistochemistry of tissue samples. Tissue samples were fixed in 10%
neutral buffered formalin (4% formaldehyde in solution), paraffin-embedded and
cut into 3 µm sections, which were mounted onto Superfrost® Plus slides (Thermo
Fisher Scientific) and air-dried. Slides were deparaffinized in xylene and re-
hydrated through a series of graded ethanol until water. Serial sections were stained
with hematoxylin and eosin. For immunohistochemistry, an automated immu-
nostaining platform was used (Ventana discovery XT; Roche, Madrid, Spain).
Antigen retrieval was first performed with high pH buffer (CC1m, Roche).
Endogenous peroxidase was blocked with 3% hydrogen peroxide and slides were
then incubated with the appropriate primary antibodies. These were anti-Oct4
(1:500, ab19857, Abcam), anti-β-Galactosidase (1:3000, AM3A9A, CNIO Mono-
clonal Antibodies Core Unit), Tfe3 (1:500, HPA023881, Atlas Antibodies, Bromma,
Sweden) or PCNA (1:1000, NA03, Merck). After the primary antibody, slides were
incubated with the species-matched secondary antibodies conjugated with horse-
radish peroxidase (Chromomap, Ventana, Roche). Immunohistochemical reactions
were developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB, Ventana,
Roche) as a chromogen, and nuclei were counterstained with hematoxylin. Finally,
the slides were dehydrated, cleared and mounted with a permanent mounting
medium (Tissue-Tek Glas Mounting Media, Sakura, Tokyo, Japan) for microscopic
evaluation. Whole digital slides were acquired with a slide scanner (Mirax Scan,
Zeiss, Jena, Germany), and images captured with the Pannoramic Viewer Software
(3DHISTECH, Budapest, Hungary).
Uncropped Images. Uncropped images of the gels displayed in the main figures
are presented in Supplementary Fig. 13
Data availability. All data generated or analyzed during this study are included in
this published article (and its supplementary information files). Raw sequencing
data are available via the accession code SRP144114 (https://www.ncbi.nlm.nih.
gov/Traces/study/?acc=SRP144114). All additional data available upon reasonable
request.
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